The Global Medical Aesthetics Market size is expected to reach $31.1 billion by 2030, rising at a market growth of 10.4% CAGR during the forecast period.
Skin aesthetic devices offer various treatment options, making them suitable for addressing skin concerns. This includes treatments for wrinkles, fine lines, acne scars, pigmentation issues, vascular conditions, and skin laxity. Therefore, the Skin Aesthetic Devices segment will capture approximately 10% share in the market by 2030. Many skins aesthetic devices are non-invasive or minimally invasive, reducing patient downtime and discomfort compared to surgical procedures. This appeals to a broad patient demographic, including those hesitant about surgery. Advancements in technology have led to skin aesthetic devices with high efficacy and safety profiles. When trained professionals use these devices, patients can achieve noticeable results with minimal risk of adverse effects.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy to keep pace with the changing demands of end users. For instance, In December, 2022, Johnson & Johnson acquired Abiomed, to broaden its offerings in the rapidly growing cardiovascular sector by incorporating heart recovery solutions into our globally leading Biosense Webster electrophysiology business. In January, 2022, Galderma S.A. took over ALASTIN Skincare, to develop products that complement company’s high-quality product lineup.
Based on the Analysis presented in the KBV Cardinal matrix; Allergan PLC and Johnson & Johnson are the forerunners in the Market. In December, 2021, Allergan PLC took over Soliton, Inc, to enhance Allergan Aesthetics’ range of non-invasive body sculpting solutions by introducing a proven method for addressing the appearance of cellulite. Companies such as Galderma S.A., Merz Pharma GmbH & Co. KGaA, Alma Lasers Ltd., are some of the key innovators in the Market.
COVID-19 Impact Analysis
During the initial phases of the pandemic, many aesthetic clinics and medical spas had to temporarily close or limit their operations due to lockdowns, social distancing measures, and concerns about virus transmission. This led to a decline in patient visits and revenue for aesthetic providers. As the pandemic unfolded, many individuals shifted their priorities away from elective cosmetic procedures toward health and safety concerns. The economic uncertainty also made some patients more cautious about discretionary spending on aesthetic treatments. The COVID-19 impact has a significant impact on the market.
Market Growth Factors
Growing Proportion of Aging Population
An aging global population has led to increased demand for medical aesthetics procedures. Individuals frequently pursue anti-aging treatments to combat fine lines, wrinkles, and sagging skin as they age. The demographic of patients seeking medical aesthetics procedures has expanded to include those in their 40s, 50s, and beyond and younger individuals interested in preventative and early intervention treatments to maintain a youthful appearance. Therefore, the aging population’s influence on the market is expected to persist as longevity increases and individuals prioritize their appearance and well-being.
Increasing Demand for Minimally Invasive and Non-Surgical Treatments
Minimally invasive and non-surgical procedures typically have shorter recovery periods than traditional surgical interventions. These treatments allow patients to resume their daily activities more rapidly, making them appealing to individuals with hectic schedules. Minimally invasive procedures generally carry a lower risk of complications compared to surgery. Patients are drawn to treatments with a lower likelihood of adverse events. The growing popularity of minimally invasive and non-surgical treatments has led to an expanding market for medical aesthetics.
Market Restraining Factors
Stringent Regulatory Compliance and Safety Standards
Stringent regulations can make it difficult for new players to enter the market. Meeting the necessary regulatory requirements and obtaining approvals can be time-consuming and expensive. Developing and testing new aesthetic products and treatments to meet safety and efficacy standards can be costly. Manufacturers may need to invest significant resources in research and development. Stringent regulatory compliance and safety standards in the market present challenges.
End User Outlook
On the basis of end user, the market is divided into clinics, hospitals, & medicals spas, beauty centres, and home care settings. In 2022, the clinics, hospitals, and medicals spas segment dominated the market with maximum revenue share. Clinics provide a safe and professional environment for patients to meet with healthcare providers, such as plastic surgeons, dermatologists, or nurse practitioners, for consultations and assessments. During these sessions, patients discuss their aesthetic goals and concerns, and healthcare providers evaluate their suitability for various treatments. Hospitals have advanced medical facilities, resources, and various medical specialists.
Procedure Outlook
Based on procedure, the medical aesthetics market is classified into surgical procedures and non-surgical procedures. The surgical procedures acquired a substantial revenue share in the medical aesthetics market in 2022. Surgical procedures in the medical aesthetics market continue to evolve with advancements in techniques and technology, focusing on achieving natural-looking results with minimized scarring and shorter recovery times. Patient safety, board-certified surgeons, and informed decision-making are essential components of the surgical aspect of medical aesthetics.
Surgical Procedures Outlook
Under surgical procedures type, the market is categorized into breast augmentation, facelift & body lift, rhinoplasty, and others. In 2022, the breast augmentation segment registered the maximum revenue share in the market. Breast augmentation is one of the most popular surgical procedures in the medical aesthetics market. Many individuals seek breast augmentation to enhance the size and shape of their breasts, improving overall body proportions and boosting self-confidence. Women of various ages and backgrounds consider breast augmentation, and it’s a procedure that appeals to a broad range of patients.
Product Outlook
By product, the market is categorized into facial aesthetic products, cosmetics implant, skin aesthetic devices, body contouring devices, physician-dispensed cosmeceuticals & skin lighteners, hair removal devices, tattoo removal devices, and others. The cosmetics implant segment covered a considerable revenue share in the market in 2022. Cosmetic implants have been a longstanding and important component of the medical aesthetics market. They are used to enhance and reshape various facial features and body contours, and they can provide long-lasting results. One of the most well-known cosmetic surgery operations is the enlargement of the breasts with silicone or saline breast implants.
Regional Outlook
Region-wise, the medical aesthetics market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the medical aesthetics market by generating the highest revenue share. Non-surgical treatments are particularly popular in North America. Common procedures include Botox and dermal filler injections, laser therapy, chemical peels, and microdermabrasion. The aging population in North America has contributed to expanding the medical aesthetics market as individuals seek treatments to address signs of aging and maintain a youthful appearance.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie, Inc.), Alma Lasers Ltd. (Sisram Medical Ltd.), Bausch Health Companies Inc, Anika Therapeutics, Inc, Johnson & Johnson, Merz Pharma GmbH & Co. KGaA, Candela corporation, Lumenis Be Ltd., Galderma S.A., and Cutera, Inc.
Recent Strategies Deployed in Medical Aesthetics Market
Acquisition and Mergers:
Jul-2023: Alma Lasers Ltd. a subsidiary of Sisram Medical Ltd. acquired PhotonMed, a medical device company focused on developing and commercializing innovative laser-based technologies for various medical and aesthetic applications. Through this acquisition, PhotonMed would signify a major step in Sisram’s strategy to directly engage with consumers, strengthening its market position and brand recognition, as the company shifts from a distribution model to a direct presence, enhancing its industry leadership.
Dec-2022: Johnson & Johnson acquired Abiomed, a leading medical device company specializing in developing and manufacturing advanced heart recovery and support technologies. Through this acquisition, Johnson & Johnson would be able to broaden its offerings in the rapidly growing cardiovascular sector by incorporating heart recovery solutions into our globally leading Biosense Webster electrophysiology business.
Jan-2022: Galderma S.A. took over ALASTIN Skincare, a company specializing in providing innovative, clinically proven skincare products and regimens that support and enhance the skin’s natural regenerative processes. Through this acquisition, both companies would develop products that complement our high-quality product lineup.
Dec-2021: Allergan PLC took over Soliton, Inc., a medical technology company specializing in developing and commercializing innovative solutions for tattoo removal and cellulite treatment. Through this acquisition, the technology and experience of Solution, Inc. would enhance Allergan Aesthetics’ range of non-invasive body sculpting solutions by introducing a proven method for addressing the appearance of cellulite.
Sep-2021: Galderma S.A. acquired Sofregen Medical, Inc, a biotechnology company dedicated to developing innovative medical solutions, with a particular focus on advancing regenerative medicine and bioengineering applications. Through this acquisition, Sofregen Medical would help Galderma in expanding its capabilities.
Sep-2020: Bausch Health Companies Inc. a subsidiary of Bausch + Lomb took over Allegro Ophthalmics, a biopharmaceutical company focused on the research and development of novel treatments for retinal diseases and eye conditions. Through this acquisition, the ophthalmic assets of Allegro would be added to the product portfolio of Bausch Health.
Apr-2019: Merz Pharma GmbH and Co. KGaA acquired Mederma, a brand in the skincare industry, recognized for its scar and stretch mark treatment products. Through this acquisition, Merz Pharma established a robust consumer healthcare foundation in the United States and aims to advance its progress through ambitious organic expansion, introducing innovative Rx to OTC switches.
Partnerships, Collaborations, and Agreements:
Sep-2021: Lumenis Be Ltd. Came into partnership with Laseraid, a leading provider of laser equipment and support services for the medical and aesthetic industries. Through this partnership, more clinics would have the opportunity to utilize Lumenis’ distinctive Splendor X technology, featuring its exclusive integrated plume evacuator and HEPA filter, enhancing safety for both operators and patients.
Jan-2020: Candela Corporation came into partnership with MT.DERM GmbH, is a company specializing in the development and manufacturing of innovative medical devices, particularly in the field of micro-needling and tattoo removal technology. Through this partnership, the Exceed medical micro needling system bolsters Candela’s product lineup, reinforcing its commitment to delivering customers a comprehensive range of leading-edge medical aesthetic technologies.
Product Launches:
Sep-2023: Cutera, Inc. introduced Secret DUO, a groundbreaking skin revitalization and resurfacing system that combines two non-ablative fractional technologies, offering the flexibility to use each method independently or in tandem to address a broad spectrum of aesthetic concerns.
Mar-2023: Galderma S.A. launched FACE, an education and training initiative offered by Galderma, focusing on the art and science of facial aesthetics, aimed at empowering healthcare professionals with the expertise and proficiency required to deliver high-quality facial aesthetic treatments.
Feb-2022: Merz Pharma GmbH and Co. KGaA launched Radiesse, a dermal filler known for its ability to restore volume, reduce wrinkles, and stimulate collagen production for long-lasting facial rejuvenation. With the launch of Radiesse, Merz Pharma would provide their clients and patients with a safe, effective, and non-invasive solution for addressing the loss of jawline contour with this approval.
Scope of the Study
Market Segments covered in the Report:
By End User


    • Clinics, Hospitals, & Medicals Spas
    • Beauty Centers
    • Home Care Settings


By Procedure


  • • Non-Surgical Procedures


o Anti-Aging And Skin Rejuvenation
o Tattoo & Scar Removal
o Hair Removal
o Lipolysis
o Others


  • • Surgical Procedures


o Breast Augmentation
o Facelift & Body Lift
o Rhinoplasty
o Others
By Product


  • • Facial Aesthetic Products
    • Body Contouring Devices
    • Hair Removal Devices
    • Physician-dispensed cosmeceuticals And Skin Lighteners
    • Cosmetics Implant
    • Skin Aesthetic Devices
    • Tattoo Removal Devices
    • Others


By Geography


  • • North America


o US
o Canada
o Mexico
o Rest of North America


  • • Europe


o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe


  • • Asia Pacific


o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific


  • • LAMEA


o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA
Companies Profiled


  • • Allergan PLC (AbbVie, Inc.)
    • Alma Lasers Ltd. (Sisram Medical Ltd.)
    • Bausch Health Companies Inc
    • Anika Therapeutics, Inc
    • Johnson & Johnson
    • Merz Pharma GmbH & Co. KGaA
    • Candela corporation
    • Lumenis Be Ltd.
    • Galderma S.A.
    • Cutera, Inc.


Unique Offerings from KBV Research


  • • Exhaustive coverage
    • Highest number of market tables and figures
    • Subscription based model available
    • Guaranteed best price
    • Assured post sales research support with 10% customization free